DDrare: Database of Drug Development for Rare Diseases

Searched query = "Alport syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = ACE I, ATA II and Statins; ACE-inhibitor; AT1-inhibitor; Atrasentan; BARDOXOLONE METHYL; Bardoxolone; Bardoxolone Methyl; Bardoxolone methyl; Benazepril; Benazepril, Valsartan and Fluvastatin; Delix; Fluvastatin; Gold; HMG-Coenzyme inhibitor (statin); Hydroxychloroquine; Lademirsen (SAR339375); Paricalcitol; RAMIPRIL; RG-012; RG012; RTA 402; Ramipril; Spironolactone; Valsartan

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04573920 (ClinicalTrials.gov)	February 1, 2021	28/9/2020	Atrasentan in Patients With Proteinuric Glomerular Diseases	A Phase 2, Open-Label, Basket Study of Atrasentan in Patients With Proteinuric Glomerular Diseases	IgA Nephropathy;Focal Segmental Glomerulosclerosis;Alport Syndrome;Diabetic Kidney Disease;Diabetic Nephropathy Type 2;Immunoglobulin A Nephropathy	Drug: Atrasentan	Chinook Therapeutics U.S., Inc.	NULL	Not yet recruiting	18 Years	N/A	All	80	Phase 2	NULL

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT04573920
(ClinicalTrials.gov)

February 1, 2021

28/9/2020

Atrasentan in Patients With Proteinuric Glomerular Diseases

A Phase 2, Open-Label, Basket Study of Atrasentan in Patients With Proteinuric Glomerular Diseases

IgA Nephropathy;Focal Segmental Glomerulosclerosis;Alport Syndrome;Diabetic Kidney Disease;Diabetic Nephropathy Type 2;Immunoglobulin A Nephropathy

Drug: Atrasentan

Chinook Therapeutics U.S., Inc.

NULL

Not yet recruiting

18 Years

N/A

All

Phase 2

NULL